Dow Down0.02% Nasdaq Up0.07%

Synageva BioPharma Corp. (GEVA)

-NasdaqGS
80.52 Up 1.44(1.82%) 4:00PM EST
Company EventsGet Company Events for:
Upcoming Events 
DateEventReminder
No Upcoming Events
Recent Events 
DateEvent
30-Oct-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
30-Oct-14Earnings announcement
22-Sep-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
9-Sep-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers
31-Jul-14SYNAGEVA BIOPHARMA CORP Files SEC form 10-Q, Quarterly Report
30-Jul-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
30-Jun-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
9-Jun-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vot
15-May-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
1-May-14SYNAGEVA BIOPHARMA CORP Files SEC form 10-Q, Quarterly Report
30-Apr-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
6-Mar-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
4-Mar-14SYNAGEVA BIOPHARMA CORP Files SEC form 10-K/A, Annual Report
3-Mar-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
26-Feb-14SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia
9-Dec-13SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
4-Nov-13SYNAGEVA BIOPHARMA CORP Files SEC form 10-Q, Quarterly Report
29-Oct-13SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
24-Oct-13SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia